<DOC>
	<DOCNO>NCT01821066</DOCNO>
	<brief_summary>A single 125 mg oral dose investigational compound PD-0332991 administer alone steady-state dose tamoxifen determine coadministration tamoxifen alters plasma pharmacokinetics PD-0332991 healthy male volunteer .</brief_summary>
	<brief_title>A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib ( PD-0332991 ) Absorption Or Elimination In Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Healthy male age 18 55 year age inclusive Body mass index ( BMI ) 17.5 30.5 kg/m2 Willing able comply schedule visit , treatment plan , laboratory test , study procedure positive urine drug screen supine systolic blood pressure &gt; 140 mm Hg , diastolic blood pressure &gt; 90 mm H. Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PD-0332991</keyword>
	<keyword>palbociclib</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>drug-drug interaction ( DDI ) study</keyword>
</DOC>